The two faces of FBW7 in cancer drug resistance

BioEssays

Volumn 33, Issue 11, 2011, Pages 851-859

  Wang, Zhiwei ^a   Fukushima, Hidefumi ^a   Gao, Daming ^a   Inuzuka, Hiroyuki ^a   Wan, Lixin ^a   Lau, Alan W ^a   Liu, Pengda ^a   Wei, Wenyi ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Drug resistance; FBW7; Mcl 1; P53; Tumor suppressor

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; GAMMA SECRETASE INHIBITOR; PACLITAXEL; SORAFENIB; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; DRUG SENSITIVITY; FBW 7 GENE; GENE LOSS; GENE TARGETING; HUMAN; NEOPLASM; PROTEIN DEGRADATION; TUMOR SUPPRESSOR GENE;

AMYLOID PRECURSOR PROTEIN SECRETASES; APOPTOSIS; BENZENESULFONATES; BIPHENYL COMPOUNDS; CELL CYCLE PROTEINS; DRUG RESISTANCE, NEOPLASM; F-BOX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MAP KINASE SIGNALING SYSTEM; MICRORNAS; NEOPLASMS; NITROPHENOLS; PACLITAXEL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION; VINCRISTINE;

EID: 80054679813     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201100101     Document Type: Article

References (100)

1. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. 2011. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 14: 150-63.
2. Wang Z, Li Y, Ahmad A, Banerjee S, et al. 2011. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33.
3. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, et al. 2006. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-34.
4. Wang Z, Li Y, Ahmad A, Azmi AS, et al. 2010. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat 13: 109-18.
5. Fletcher JI, Haber M, Henderson MJ, Norris MD. 2010. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10: 147-56.
6. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
7. Burger H, Loos WJ, Eechoute K, Verweij J, et al. 2011. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 14: 22-34.
8. Singh A, Settleman J. 2010. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-51.
9. Marin JJ, Castano B, Blazquez AG, Rosales R, et al. 2010. Strategies for overcoming chemotherapy resistance in enterohepatic tumours. Curr Mol Med 10: 467-85.
10. Wang Y, Cabral F. 2005. Paclitaxel resistance in cells with reduced beta-tubulin. Biochim Biophys Acta 1744: 245-55.
11. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, et al. 2010. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29: 2346-56.
12. Dean M, Fojo T, Bates S. 2005. Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-84.
13. Ding XW, Wu JH, Jiang CP. 2010. ABC G2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 86: 631-7.
14. Baselga J. 2011. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16: 12-9.
15. Karnak D, Xu L. 2010. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets 11: 699-707.
16. Dhillon KK, Swisher EM, Taniguchi T. 2011. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 102: 663-9.
17. Ku JL, Shin YK, Kim DW, Kim KH, et al. 2010. Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers. Carcinogenesis 31: 1003-9.
18. Zwart W, Rondaij M, Jalink K, Sharp ZD, et al. 2009. Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1. Mol Endocrinol 23: 1335-45.
19. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, et al. 2008. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22: 708-22.
20. Carr JR, Park HJ, Wang Z, Kiefer MM, et al. 2010. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70: 5054-63.
21. Wang Z, Ahmad A, Li Y, Banerjee S, et al. 2010. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev 36: 151-6.
22. Di Fiore F, Sesboue R, Michel P, Sabourin JC, et al. 2010. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 103: 1765-72.
23. Kono SA, Marshall ME, Ware KE, Heasley LE. 2009. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat 12: 95-102.
24. Hixon ML, Paccagnella L, Millham R, Perez-Olle R, et al. 2010. Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway. Rev Recent Clin Trials 5: 189-208.
25. Pratilas CA, Solit DB. 2010. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 16: 3329-34.
26. Haagenson KK, Wu GS. 2010. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 29: 143-9.
27. Jiang BH, Liu LZ. 2008. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11: 63-76.
28. Li F, Sethi G. 2010. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 1805: 167-80.
29. Baud V, Karin M. 2009. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8: 33-40.
30. Wang Z, Li Y, Ahmad A, Azmi AS, et al. 2010. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta 1806: 258-67.
31. Wang Z, Li Y, Kong D, Banerjee S, et al. 2009. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69: 2400-7.
32. Wang Z, Ahmad A, Li Y, Kong D, et al. 2010. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 1806: 122-30.
33. Zhang S, Yu D. 2010. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 16: 4325-30.
34. Cheung CH, Cheng L, Chang KY, Chen HH, et al. 2011. Investigations of survivin: the past, present and future. Front Biosci 16: 952-61.
35. Inuzuka H, Fukushima H, Shaik S, Liu P, et al. 2011. Mcl-1 ubiquitination and destruction. Oncotarget 2: 239-44.
36. Inuzuka H, Shaik S, Onoyama I, Gao D, et al. 2011. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471: 104-9.
37. Wertz IE, Kusam S, Lam C, Okamoto T, et al. 2011. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471: 110-4.
38. Crusio KM, King B, Reavie LB, Aifantis I. 2010. The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation. Oncogene 29: 4865-73.
39. Welcker M, Clurman BE. 2008. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83-93.
40. Bedford L, Lowe J, Dick LR, Mayer RJ, et al. 2011. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 10: 29-46.
41. Hoeller D, Dikic I. 2009. Targeting the ubiquitin system in cancer therapy. Nature 458: 438-44.
42. Jin J, Cardozo T, Lovering RC, Elledge SJ, et al. 2004. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev 18: 2573-80.
43. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, et al. 2001. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294: 173-7.
44. Minella AC, Welcker M, Clurman BE. 2005. Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc Natl Acad Sci USA 102: 9649-54.
45. Yada M, Hatakeyama S, Kamura T, Nishiyama M, et al. 2004. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23: 2116-25.
46. Welcker M, Orian A, Jin J, Grim JE, et al. 2004. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101: 9085-90.
47. Wei W, Jin J, Schlisio S, Harper JW, et al. 2005. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8: 25-33.
48. Hoeck JD, Jandke A, Blake SM, Nye E, et al. 2010. Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nat Neurosci 13: 1365-72.
49. Babaei-Jadidi R, Li N, Saadeddin A, Spencer-Dene B, et al. 2011. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J Exp Med 208: 295-312.
50. Tetzlaff MT, Yu W, Li M, Zhang P, et al. 2004. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc Natl Acad Sci USA 101: 3338-45.
51. Rocher-Ros V, Marco S, Mao JH, Gines S, et al. 2010. Presenilin modulates EGFR signaling and cell transformation by regulating the ubiquitin ligase Fbw7. Oncogene 29: 2950-61.
52. Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, et al. 2005. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab 1: 379-91.
53. Punga T, Bengoechea-Alonso MT, Ericsson J. 2006. Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J Biol Chem 281: 25278-86.
54. Fu L, Kim YA, Wang X, Wu X, et al. 2009. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 69: 8967-76.
55. Liu N, Li H, Li S, Shen M, et al. 2010. The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem 285: 18858-67.
56. Zhao D, Zheng HQ, Zhou Z, Chen C. 2010. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res 70: 4728-38.
57. Thompson BJ, Jankovic V, Gao J, Buonamici S, et al. 2008. Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med 205: 1395-408.
58. Finkin S, Aylon Y, Anzi S, Oren M, et al. 2008. Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy. Oncogene 27: 4411-21.
59. Tsunematsu R, Nakayama K, Oike Y, Nishiyama M, et al. 2004. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem 279: 9417-23.
60. Onoyama I, Tsunematsu R, Matsumoto A, Kimura T, et al. 2007. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med 204: 2875-88.
61. Matsuoka S, Oike Y, Onoyama I, Iwama A, et al. 2008. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 22: 986-91.
62. Akhoondi S, Lindstrom L, Widschwendter M, Corcoran M, et al. 2010. Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res 12: R105.
63. Sancho R, Jandke A, Davis H, Diefenbacher ME, et al. 2010. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology 139: 929-41.
64. O'Neil J, Look AT. 2007. Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene 26: 6838-49.
65. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, et al. 2007. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67: 9006-12.
66. Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, et al. 2004. Inactivation of hCDC4 can cause chromosomal instability. Nature 428: 77-81.
67. Spruck CH, Strohmaier H, Sangfelt O, Muller HM, et al. 2002. hCDC4 gene mutations in endometrial cancer. Cancer Res 62: 4535-9.
68. Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, et al. 2009. Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene 28: 2393-405.
69. Kitagawa K, Kotake Y, Hiramatsu Y, Liu N, et al. 2010. GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms. Cell Div 5: 27.
70. O'Neil J, Grim J, Strack P, Rao S, et al. 2007. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 204: 1813-24.
71. Thompson BJ, Buonamici S, Sulis ML, Palomero T, et al. 2007. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 204: 1825-35.
72. Yau T, Pang R, Chan P, Poon RT. 2010. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib. Expert Opin Pharmacother 11: 2187-98.
73. Panka DJ, Cho DC, Atkins MB, Mier JW. 2008. GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem 283: 726-32.
74. Huber S, Oelsner M, Decker T, zum Buschenfelde, CM, et al. 2011. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 25: 838-47.
75. Minella AC, Clurman BE. 2005. Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle 4: 1356-9.
76. Sharma SV, Settleman J. 2007. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214-31.
77. Cragg MS, Harris C, Strasser A, Scott CL. 2009. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 9: 321-6.
78. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, et al. 2006. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-99.
79. Baird RD, Tan DS, Kaye SB. 2010. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 7: 575-82.
80. Kavallaris M. 2010. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10: 194-204.
81. Moore A, Pinkerton R. 2009. Vincristine: can its therapeutic index be enhanced? Pediatr Blood Cancer 53: 1180-7.
82. Rizzo P, Osipo C, Foreman K, Golde T, et al. 2008. Rational targeting of Notch signaling in cancer. Oncogene 27: 5124-31.
83. Wang Z, Li Y, Sarkar FH. 2010. Notch signaling proteins: legitimate targets for cancer therapy. Curr Protein Pept Sci 11: 398-408.
84. Ranganathan P, Weaver KL, Capobianco AJ. 2011. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 11: 338-51.
85. Demarest RM, Ratti F, Capobianco AJ. 2008. It's T-ALL about Notch. Oncogene 27: 5082-91.
86. Real PJ, Ferrando AA. 2009. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia 23: 1374-7.
87. Maser RS, Choudhury B, Campbell PJ, Feng B, et al. 2007. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447: 966-71.
88. Mao JH, Perez-Losada J, Wu D, Delrosario R, et al. 2004. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432: 775-9.
89. Yokobori T, Mimori K, Iwatsuki M, Ishii H, et al. 2009. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 69: 3788-94.
90. Welcker M, Larimore EA, Frappier L, Clurman BE. 2011. Nucleolar targeting of the fbw7 ubiquitin ligase by a pseudosubstrate and glycogen synthase kinase 3. Mol Cell Biol 31: 1214-24.
91. Balamurugan K, Wang JM, Tsai HH, Sharan S, et al. 2010. The tumour suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J 29: 4106-17.
92. Lerner M, Lundgren J, Akhoondi S, Jahn A, et al. 2011. miRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle 10: 2172-83.
93. Cheok CF, Verma CS, Baselga J, Lane DP. 2011. Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37.
94. Sarkar FH, Li Y, Wang Z, Kong D, et al. 2010. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 13: 57-66.
95. Huntzinger E, Izaurralde E. 2011. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 12: 99-110.
96. Xu Y, Sengupta T, Kukreja L, Minella AC. 2010. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem 285: 34439-46.
97. Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, et al. 2011. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet 43: 673-8.
98. Zhao X, Yang L, Hu J. 2011. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 30: 55.
99. Feng DD, Zhang H, Zhang P, Zheng YS, et al. 2010. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukemia. J Cell Mol Med in press, DOI: 10.1111/j.1582-4934.2010.01213.x.
100. Duensing S, Duensing A. 2010. Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors. Oncotarget 1: 6-8.